🔗 Share this article

Government ministers and leading parliamentarians have raised concerns that the United Kingdom's series of deals with Donald Trump are "fundamentally unstable." This stems from revelations that a much-touted deal on pharmaceutical tariffs, which pledges zero tariffs in exchange for the NHS facing higher prices, lacks any detailed agreement beyond vague headline terms published in government press releases.

An Agreement in Principle Only

The arrangement concerning medicines, hailed as a "generational" achievement, remains an "agreement in principle" without a signed legal text. Observers point out that the public statements from the UK and US governments frame the deal in divergent terms. The British version emphasizes securing "duty-free access" as a singular success, while the American announcement highlights the expectation for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has agreed to terms to increase medicine costs in return for nothing more than a verbal promise from President Trump," said David Henig, a trade policy analyst. "We know he has form for not keeping promises."

Broader Instability and a Paused Tech Deal

Concerns have been intensified by Washington's move to pause the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US cited a insufficient movement from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an earlier tariff deal have still not been formally ratified by the US, despite a fast-approaching January deadline. "It is our belief that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have admitted unease that the government's US-UK accords are lacking substance. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another described the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, remarked: "What is even more astonishing than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a good faith actor. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Ministry sources have attempted to minimize the risk of the US backing out of the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it less abstract than the paused tech deal.

Officials admit that unpredictability is a feature of dealing with the Trump administration. However, they maintain that the UK has obtained tangible results for businesses, such as preferential tariff rates compared to other nations. "The fact we have 25% steel tariffs, which is better than the rate for the rest of the world, is a concrete advantage," one official said.

Nevertheless, delays have emerged in enacting the May tariff agreement. Promised access for British beef have not materialized, and the assurance to "reduce steel tariffs to zero" has is still pending, with tariffs staying at 25%.

Looking ahead, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.